Abstract
Objective
To evaluate the potential role of neutrophil-to-lymphocyte ratio (NLR) with therapeutic response in patients who were treated with docetaxel for mCRPC.
Materials and methods
We retrospectively analyzed the clinical data from 111 consecutive patients who were treated with docetaxel for mCRPC from 2009 to 2016 in a single center from Northwestern China. Pretreatment baseline and follow-up data including age, PSA response, Gleason score, and cycle number were reviewed, and multivariable Cox regression models and Kaplan–Meier analysis were used to predict overall survival (OS) and progression-free survival (PFS).
Results
In Kaplan–Meier analyses, the NLR (optimal threshold 3.3), total PSA response, number of chemotherapy cycles, stage T, baseline of PSA, albumin, presence of visceral metastases, and PSA level at the diagnosis of cancer were significantly associated with OS, respectively. In multivariable analyses, higher NLR (>3.3), PSA level at the diagnosis of cancer (≥162 ng/ml), number of chemotherapy cycles, and albumin (<40.5 g/l) were associated with increased risk of death, respectively. Meanwhile, young age, higher NLR, number of chemotherapy cycles, presence of visceral metastases, and poor PSA response were associated with shorter PFS.
Conclusion
NLR combined with PSA level at the diagnosis of cancer remains an important prognostic marker in predicting therapeutic outcome in Chinese men who receive chemotherapy for mCRPC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30
Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132
Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1):34–45
Pezaro C, Attard G (2012) Prostate cancer in 2011: redefining the therapeutic landscape for CRPC. Nat Rev Urol 9(2):63–64
Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513–1520
Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512
Halabi S, Small EJ, Kantoff PW et al (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21(7):1232–1237
Qu YY, Dai B, Kong YY et al (2013) Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl 15(1):110–115
Smaletz O, Scher HI, Small EJ et al (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20(19):3972–3982
Zhang W, Meng Y, Liu N, Wen XF, Yang T (2015) Insights into chemoresistance of prostate cancer. Int J Biol Sci 11(10):1160–1170
Wu K, Xie D, Zou Y et al (2013) The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer Res 19(17):4740–4749
Gu X, Gao X, Li X et al (2016) Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients. Sci Rep 6:22089
Tang L, Li X, Wang B et al (2016) Prognostic value of neutrophil-to-lymphocyte ratio in localized and advanced prostate cancer: a systematic review and meta-analysis. PLoS ONE 11(4):e153981
Jang WS, Cho KS, Kim KH et al (2016) Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy in localized prostate cancer. Prostate Cancer Prostatic Dis 19(3):298–304
Kawahara T, Fukui S, Sakamaki K et al (2015) Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget 6(31):32169–32176
Lorente D, Mateo J, Templeton AJ et al (2015) Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol 26(4):750–755
Van Soest RJ, Templeton AJ, Vera-Badillo FE et al (2015) Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol 26(4):743–749
Conteduca V, Crabb SJ, Jones RJ et al (2016) Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS ONE 11(7):e158952
Keizman D, Gottfried M, Ish-Shalom M et al (2012) Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist 17(12):1508–1514
Leibowitz-Amit R, Templeton AJ, Omlin A et al (2014) Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol 25(3):657–662
Nuhn P, Vaghasia AM, Goyal J et al (2014) Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int 114(6b):E11–E17
Sumbul AT, Sezer A, Abali H et al (2014) Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Urol Nephrol 46(8):1531–1535
Lolli C, Caffo O, Scarpi E et al (2016) Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone. Front Pharmacol 7:376
Li YF, Zhang SF, Zhang TT et al (2013) Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison. Asian J Androl 15(6):773–779
Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6(1):149–163
Acknowledgements
This study was partially supported by the National Natural Science Foundation of China (NSFC 81202014 to KW, NSFC 81130041 to DH) and the Fundamental Research Funds for the Central Universities (to KW).
Author contributions
DLH, KJW, and XQP designed the study, analyzed, and interpreted the clinical data, wrote, and revised the manuscript. XQP, GT, WL, YMJ, DPW and JHF collected the clinical data and engaged in patient follow-up. DLH and KJW supervised the project and revised the manuscript. All the listed authors have participated actively in the study and approved the submitted manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the First Affiliated Hospital of Xi’an Jiaotong University and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Pei, Xq., He, Dl., Tian, G. et al. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China. Int Urol Nephrol 49, 629–635 (2017). https://doi.org/10.1007/s11255-017-1524-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-017-1524-z